Literature DB >> 6630784

Electrophysiologic actions of high plasma concentrations of propranolol in human subjects.

H J Duff, D M Roden, L Brorson, A J Wood, A K Dawson, R K Primm, J A Oates, R F Smith, R L Woosley.   

Abstract

The authors have previously shown that 40% of patients whose ventricular arrhythmias respond to propranolol require plasma concentrations in excess of those producing substantial beta-receptor blockade (greater than 150 ng/ml). However, the electrophysiologic actions of propranolol have only been examined in human beings after small intravenous doses achieving concentrations of less than 100 ng/ml. In this study, the electrophysiologic effects of a wider concentration range of propranolol was examined in nine patients. Using a series of loading and maintenance infusions, measurements were made at baseline, at low mean plasma propranolol concentrations (104 +/- 17 ng/ml) and at high concentrations (472 +/- 68 ng/ml). Significant (p less than 0.05) increases in AH interval and sinus cycle length were seen at low concentrations of propranolol, with no further prolongation at the high concentrations; these effects are typical of those produced by beta-blockade. However, progressive shortening of the endocardial monophasic action potential duration and QTc interval were seen over the entire concentration range tested (p less than 0.05). At high concentrations, there was significant (p less than 0.05) further shortening of both the QTc and monophasic action potential duration beyond that seen at low propranolol concentrations, along with a progressive increase in the ratio of the ventricular effective refractory period to monophasic action potential duration. No significant changes were seen in HV interval, QRS duration or ventricular effective refractory period. In summary, the concentration-response relations for atrioventricular conductivity and sinus node automaticity were flat above concentrations of 150 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630784     DOI: 10.1016/s0735-1097(83)80340-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

Authors:  Rebecca C Ahrens-Nicklas; Colleen E Clancy; David J Christini
Journal:  Cardiovasc Res       Date:  2009-03-05       Impact factor: 10.787

3.  Effects of propranolol on ventricular repolarization in man.

Authors:  K Endresen; J P Amlie
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade.

Authors:  K T Murray; C Reilly; R P Koshakji; D M Roden; M D Lineberry; A J Wood; L A Siddoway; J T Barbey; R L Woosley
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 5.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 6.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

7.  Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.

Authors:  Dao W Wang; Lia Crotti; Wataru Shimizu; Matteo Pedrazzini; Francesco Cantu; Paolo De Filippo; Kanako Kishiki; Aya Miyazaki; Tomoaki Ikeda; Peter J Schwartz; Alfred L George
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-12-02

8.  Propranolol blocks cardiac and neuronal voltage-gated sodium channels.

Authors:  Dao W Wang; Akshitkumar M Mistry; Kristopher M Kahlig; Jennifer A Kearney; Jizhou Xiang; Alfred L George
Journal:  Front Pharmacol       Date:  2010-12-31       Impact factor: 5.810

9.  Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.

Authors:  Eddy Pasquier; Joseph Ciccolini; Manon Carre; Sarah Giacometti; Raphaelle Fanciullino; Charlotte Pouchy; Marie-Pierre Montero; Cindy Serdjebi; Maria Kavallaris; Nicolas André
Journal:  Oncotarget       Date:  2011-10

10.  Total beta-adrenoceptor knockout slows conduction and reduces inducible arrhythmias in the mouse heart.

Authors:  Florian Stöckigt; Klara Brixius; Lars Lickfett; René Andrié; Markus Linhart; Georg Nickenig; Jan Wilko Schrickel
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.